Sakhi H, Dahmane D, Attias P, et al. - In view of the poor understanding concerning the humoral response over time against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), researchers sought to determine the long-term kinetics of the antibody response to SARS-CoV-2 (specifically, IgG against nucleocapsid and spike antigens) in 83 patients on in-center hemodialysis who recovered from coronavirus disease 2019 (COVID-19). No initial seroconversion was identified in 10% of patients, which was linked with immunocompromised status; patients with seroconversion showed decaying in IgG antibodies over time. Following factors were noted to be linked with this decline: older age, female gender, and nonsevere clinical presentation. After 6 months, there were nearly 25% of patients who had negative IgG antinucleocapsid serology, whereas antispike antibodies remained maintained in most patients. By defining the evolution of the SARS-CoV-2 antibody response, these findings might aid in better characterizing future therapeutic and preventive approaches against COVID-19 in patients on hemodialysis.